Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (VRX) announced Wednesday that it's buying skin-cream maker Obagi Medical Products (OMPI) for $344 million, sending both shares up in the …
Boath
James O’Connor, director at Pharma Glass, said it had previously been difficult to readily source from stock Ompi products in the UK and Ireland. “Pharma Glass Vials and Closures is now building up inventory to meet …
Pharmaceutical packaging
The stock is now up 18.69% to $16.93 after creating a new 52-week ... at the JMP Securities failed to defend …
Another chapter has been written on the nearly year-long effort by Voce Capital management to get Obagi Medical Products (OMPI) sold. On Monday ... own due diligence before buying and selling any stock, and/or consult …
OMPI). Let's dive right in. Zumiez could zoom The day started off with a bright note for "action sports" retailer Zumiez. Ascendiant Capital initiated coverage of the stock with a buy rating Thursday, sending Zumiez shares …
Among the companies with shares expected to actively trade in Tuesday’s session are BGC Partners Inc. (BGCP), Obagi Medical Products Inc. (OMPI) and Humana Inc. (HUM ... eSpeed platform from BGC in a cash …
This excerpt taken from the OMPI 10-K filed Mar 15, 2007 ... the Company declared and paid a $3.60 per share common stock dividend, totaling approximately $63,088, in cash. A substantial portion of the common stock
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that it has entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Obagi Medical …
Valeant Pharmaceuticals
Obagi Medical Products (OMPI): Roth Capital reduces its rating to Neutral from ... from Market Outperform by brokerage boutique Brinson Patrick. (See also: New Stock Coverage: Scarlet Letter for Crimson Exploration …